Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | EYA2 | O00167 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12650480 | 1.00 | TDP1 (0.52) | TDP1EYA2APPACEBLM | |
| SCHEMBL1251434 | 1.00 | TDP1 (0.52) | TDP1EYA2APPACEBLM | |
| SCHEMBL28287740 | 0.95 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL10092610 | 0.88 | TDP1 (0.47) | TDP1EYA2APPACEBLM | |
| SCHEMBL3891142 | 0.88 | TDP1 (0.47) | TDP1EYA2APPACEBLM | |
| SCHEMBL8412960 | 0.86 | TDP1 (0.45) | TDP1EYA2APPACEBLM | |
| SCHEMBL12363885 | 0.85 | TDP1 (0.44) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL6341387 | 0.85 | TET2 (0.40) | TDP1EYA2APPACEBLM | |
| SCHEMBL168206 | 0.82 | TET2 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL2849431 | 0.82 | TET2 (0.44) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| US-11110185-B2 | Combination formulation | GE HEALTHCARE AS (NO) | 2021-09-07 | — | — | US | claimed |
| US-20180303960-A1 | Combination Formulation | GE HEALTHCARE AS (NO) | 2018-10-25 | — | — | US | claimed |
| EP-3383441-A1 | FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS | GE Healthcare AS (NO) | 2018-10-10 | — | — | EP | claimed |
| WO-2017093336-A1 | FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2017-06-08 | — | — | WO | claimed |
| EP-2373322-A1 | PROBIOTIC FORMULATIONS | Bracco Imaging S.p.A (IT) | 2011-10-12 | — | — | EP | claimed |
| US-20110206650-A1 | Probiotic Formulations | BRACCO IMAGING S.P.A. (IT) | 2011-08-25 | — | — | US | claimed |
| US-7780952-B2 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING SPA (IT) | 2010-08-24 | — | — | US | claimed |
| EP-2206506-A1 | Probiotic formulations | Bracco Imaging S.p.A (IT) | 2010-07-14 | — | — | EP | claimed |
| WO-2010069920-A1 | PROBIOTIC FORMULATIONS | BRACCO IMAGING SPA (IT) | 2010-06-24 | — | — | WO | claimed |
| EP-1509254-B1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING SPA (IT) | 2009-01-14 | — | — | EP | claimed |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1509254-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | Bracco Imaging S.p.A. (IT) | 2005-03-02 | — | — | EP | claimed |
| WO-2003103722-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING S.P.A. (IT) | 2003-12-18 | — | — | WO | claimed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | claimed |
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260077070-A1 | METHOD FOR INCREASING DISPERSION STABILITY OF NANOPARTICLES AS T1 MRI CONTRAST AGENT AND T1 MRI CONTRAST NANOPARTICLES | INVENTERA INC. (KR) | 2026-03-19 | — | — | US | disclosed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003004518-A2 | CORTISTATIN ANALOGS CAPABLE OF BINDING SELECTIVELY TO GROWTH HORMONE SECRETAGOGUE RECEPTORS | ARDANA BIOSCIENCE LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002094873-A2 | PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS, AND THEIR THERAPEUTIC AND DIAGNOSTIC USE | BRACCO IMAGING S.P.A. (IT) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110185-B2 | Combination formulation | SLC10A1, SLC10A2, RXFP2 | TDP1 3864/4885EYA2 3399/4885APP 2979/4885 |
| US-20260077070-A1 | METHOD FOR INCREASING DISPERSION STABILITY OF NANOPARTICLES AS T1 MRI CONTRAST AGENT AND T1 MRI CONTRAST NANOPARTICLES | H1-3, MUC1, TRHDE | TDP1 2421/4885EYA2 3922/4885APP 3831/4885 |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | SLC7A5, SLC2A9, SLC2A1 | TDP1 4056/4885EYA2 4715/4885APP 1759/4885 |
| US-20180303960-A1 | Combination Formulation | SLC10A1, SLC10A2, RXFP2 | TDP1 3864/4885EYA2 3399/4885APP 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.